Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Caribou Biosciences, Inc.NASDAQ: CRBU

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $8.07M fell 17.1% year over year, behind the -1.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Selling, general & admin amounted to 339.8% of revenue in FY2025, down 125.1 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $25M (-34.1%) for the fiscal year ending Dec 2026, a slowdown from the -18.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.07M-6.0% QoQ
Last fiscal yearDec 2025
$37.91M-18.4% YoY
LTMMar 2026
$36.25M-1.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.1%-37.2%-20.0 pp
1 year-18.4%-34.1%-15.7 pp
3-year CAGR-0.1%-15.7%-15.6 pp
5-year CAGR+48.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
37.91M USD
Year-over-year change
-18.4%
4-year CAGR
+12.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.5% is the 4th highest of 11, against a peer median of -7.4%.
  • Selling, general & admin amounts to 323.5% of revenue for CRBU, versus a peer median of 136.2%.
CRBU Competitors
Selling, General & Admin for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M USD-25.4%-1.1%55.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M USD-1.5%-0.1%323.5%
HUMAHumacyte, Inc.LTM Mar 2026$27.31M USD-10.2%+10.9%1354.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$26.89M USD-3.6%-3.6%95.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M USD-4.5%+3.4%10537.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$21.38M USD-22.5%-9.9%127.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$20.02M USD-13.1%-15.9%144.4%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$16.97M USD+137.1%+72.2%—
Peer median (excluding CRBU) —-7.4%+1.1%136.2%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.